Myron E. Schwartz
- PROFESSOR Surgery, Surgical Oncology
American Board of Surgery
MD, Jefferson Medical College
Mercy Catholic Medical Center
Mount Sinai Hospital
Fellowship, Vascular Surgery
Mount Sinai Hospital
Myron Schwartz, MD
The Henry Kaufmann Professor of Surgery
Director of Liver Surgery
Recanati/Miller Transplantation Institute
The Mount Sinai Medical Center, New York
Dr. Schwartz graduated from Jefferson Medical College AOA in 1976. After a year of rotating internship he joined the National Health Service Corps for three years as a general practitioner in rural Virginia. Dr. Schwartz came to Mount Sinai in 1981, completed residencies in general and vascular surgery, and joined the faculty in 1987. He worked with Charles Miller, MD to establish the Mount Sinai Liver Transplant Program in 1988, and since then has devoted his career to hepatobiliary surgery and transplantation. Over the years he has served as Director of Pediatric and Adult Liver Transplantation, and more recently has focused on liver cancer. Dr. Schwartz is currently the Clinical Director of the Mount Sinai Liver Cancer Program. Together with Research Director Josep Llovet MD, Dr Schwartz has led the collaborative effort that has put Mount Sinai at the forefront world-wide in liver cancer clinical care and clinical/translational research. Dr Schwartz has been funded by the NIH through a K24 Career Development Award entitled, “Systematic Integration of Patient-Oriented Research into the Clinical Pathway for Hepatocellular Carcinoma”. He has published over 300 papers in peer-reviewed journals, as well as 21 book chapters. Dr. Schwartz is an international authority on hepatic resection and transplantation for liver cancer, a subject about which he lectures frequently both in the U.S. and around the world.In the News:
Dr. Schwartz and his work was profiled in The Daily News feature The Daily Check Up. View the PDF.
Physician of the Year Award
Transplant Recipients International Organization
Arthur Aufses, Sr., Prize in Surgery
Alpha Omega Alpha Medical Honor Society
- <!--[if !supportLists]-->Hepatobiliary Surgery
- <!--[endif]-->Liver Tumors
- Liver Cancer
- Liver Donor Liver Transplantation
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 Apr; 144(4).
Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (Baltimore, Md.) 2013 Apr; 57(4).
Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of hepatology 2011 Dec; 55(6).
Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011 May; 140(5).
Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz ME. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8: 208-212.
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009 Jul; 137(1).
Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009 Sep; 137(3).
Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. Journal of hepatology 2008 Oct; 49(4).
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 2008 Nov; 359(19).
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. The lancet oncology 2009 Jan; 10(1).
Roayaie S, Schwartz JD, Sung M, Emre S, Miller CM, Gondolesi G, Krieger N, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 2004; 10: 534-540.
Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: S268-276.
Gondolesi G, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein T, Emre S, Miller CM, Schwartz ME. Adult Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: Extending UNOS Priority Criteria. Ann Surg 2004; 239: 142-149.
Gondolesi GE, Goldman J, Wayne M, Florman S, Schwartz ME, Miller CM, Emre S. .;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Schwartz during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Gilead Sciences, Inc.; Inova Diagnostics, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
5 East 98th Street
12th Floor, Box 1104
New York, NY 10029
- Wednesday 9:00am - 5:00pm
- Friday 9:00am - 1:00pm
- Farsi (Persian)
- Aetna HMO
- Aetna PPO
- Beech Street
- CIGNA Healthcare HMO
- Cigna - PPO
- Devon Health Services
- Empire Blue Cross/ Blue Shield - HMO
- Empire Blue Cross/Blue Shield
- Empire Plan for Government Employees
- Fidelis Care NY
- First Health
- GHI HMO
- Group Health Insurance, Inc.
- HIP Commercial
- HIP Medicaid
- HIP Medicare
- HealthFirst/Medicaid HMO
- HealthPlus, Inc.
- Medicaid New Jersey
- MetroPlus Health Plan
- Neighborhood Health Providers, LLC
- Oxford (Medicare)
- Oxford Health Plans
- Oxford Health Plans - HMO
- Oxford Liberty
- Railroad Medicare
- United Health Care Empire Plan
- United Healthcare
- American Express
- Personal Check
168 Centre Street, 3M
New York, NY 10013